Skip to content

PDS Biotechnology Corp: 10-Q filed 2016-11-01

What PDS Biotechnology Corp reported in its quarterly report filed 2016-11-01 (fiscal Q3 2016): 25 published measures, 67 facts as tagged in accession 0001140361-16-084377.

This filing

Form
10-Q (quarterly report)
Filed
2016-11-01
Fiscal period
fiscal Q3 2016
Accession
0001140361-16-084377 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All PDS Biotechnology Corp filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2016-09-30116,579,228USD
At 2015-12-31134,092,658USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2016-09-3097,508,147USD
At 2015-12-31122,477,527USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2016-09-30112,784,622USD
At 2015-12-31130,189,421USD
At 2015-09-3052,879,907USD
At 2014-12-3113,728,972USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2016-07-01 to 2016-09-30-10,759,262USD92
2016-01-01 to 2016-09-30-29,305,801USD274
2015-07-01 to 2015-09-30-10,130,050USD92
2015-01-01 to 2015-09-30-20,119,498USD273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2016-01-01 to 2016-09-30339,410USD274
2015-01-01 to 2015-09-30799,424USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2016-09-30-91,559,771USD
At 2015-12-31-62,253,970USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2016-09-303,291,873USD
At 2015-12-312,766,992USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2016-01-01 to 2016-09-304,029,326USD274
2015-01-01 to 2015-09-301,566,562USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2016-07-01 to 2016-09-30-10,276,792USD92
2016-01-01 to 2016-09-30-28,573,347USD274
2015-07-01 to 2015-09-30-8,484,860USD92
2015-01-01 to 2015-09-30-17,627,438USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2016-09-30113,144,485USD
At 2015-12-31131,270,505USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2016-07-01 to 2016-09-30375,089USD92
2016-01-01 to 2016-09-30717,263USD274
2015-07-01 to 2015-09-30213,021USD92
2015-01-01 to 2015-09-30615,047USD273

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2016-09-304,253,599USD
At 2015-12-318,589,708USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2016-09-301,963,350USD
At 2015-12-312,584,249USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2016-07-01 to 2016-09-3010,276,792USD92
2016-01-01 to 2016-09-3028,573,347USD274
2015-07-01 to 2015-09-308,484,860USD92
2015-01-01 to 2015-09-3017,627,438USD273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2016-07-01 to 2016-09-306,724,503USD92
2016-01-01 to 2016-09-3018,046,572USD274
2015-07-01 to 2015-09-306,507,972USD92
2015-01-01 to 2015-09-3012,574,455USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2016-09-3028,915,226shares
At 2015-12-3128,810,845shares

Long-term debt

Long-term borrowings under this concept, which can include the current portion depending on presentation. It is not total liabilities and may exclude leases and other obligations.

PeriodValueUnitDays
At 2016-09-3015,000,000USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2016-09-30142,870USD
At 2015-12-3155,161USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2016-09-302,290,249USD
At 2015-12-313,734,348USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2016-09-30359,863USD
At 2015-12-311,081,084USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2016-07-01 to 2016-09-30-10,759,262USD92
2016-01-01 to 2016-09-30-29,305,801USD274
2015-07-01 to 2015-09-30-10,130,050USD92
2015-01-01 to 2015-09-30-20,119,498USD273

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2016-07-01 to 2016-09-30-10,759,262USD92
2016-01-01 to 2016-09-30-29,305,801USD274
2015-07-01 to 2015-09-30-11,957,618USD92
2015-01-01 to 2015-09-30-24,376,581USD273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2016-07-01 to 2016-09-303,552,289USD92
2016-01-01 to 2016-09-3010,526,775USD274
2015-07-01 to 2015-09-301,976,888USD92
2015-01-01 to 2015-09-305,052,983USD273

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2016-01-01 to 2016-09-3060,331USD274
2015-01-01 to 2015-09-3038,360USD273

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2016-01-01 to 2016-09-30-399,708USD274
2015-01-01 to 2015-09-30-126,415USD273

Inspect the source

Entity
PDS Biotechnology Corp / CIK 0001472091
Captured
2026-09-20T09:07:40.584Z
SEC response SHA-256
69e1cee7a201b49964a3008a5c2ec76eaaf5723c75824c2caf8a2c52d86edef2

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001472091.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))